AACR 2026 – private biotechs score plenaries
Circle Pharma and Verismo feature in coveted sessions.
AACR 2026 – one more shot for integrins
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
AACR 2026 – conjugates remain centre stage
Single, double and even triple-payload ADCs will be presented at the meeting.
AACR 2026 – Merck’s VEGF bispecific reveal
First human data on MK-2010 are imminent.
ASCO-GU – J&J looks to a pasritamig combo
New data with pasritamig plus docetaxel support a recent pivotal start.
ASCO-GU – Flare hits an “undruggable” target
But biomarker enrichment and toxicity remain key for FX-909.
ASCO-GU 2026 – gauging Welireg’s double win
Welireg looks headed to regulators in second-line and adjuvant kidney cancer.
ASCO-GU – Padcev and Keytruda impress again
The combo gets another slam dunk, this time in perioperative chemo-eligible MIBC.
ASCO-GU 2026 – Protara gets that sinking feeling
TARA-002 goes from looking better than Inlexzo to seeming rather worse.
